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RNA viruses are a major threat to animals and plants. RNA interference (RNAi) and the 32 
interferon response provide innate antiviral defense against RNA viruses. Here we 33 
performed a large-scale screen using C. elegans and its natural pathogen, the Orsay virus 34 
(OrV), and identified cde-1 as important for antiviral defense. CDE-1 is a homologue of 35 
the mammalian TUT4 and TUT7 (collectively called TUT4(7)) terminal 36 
uridylyltransferases; its catalytic activity is required for its antiviral function. CDE-1 37 
uridylates the 3ʹ end of the OrV RNA genome and promotes its degradation, independently 38 
of the RNAi pathway. Likewise, TUT4(7) uridylate influenza A virus (IAV) mRNAs in 39 
mammalian cells. Deletion of TUT4(7) leads to increased IAV mRNA and protein levels. 40 
We have defined 3ʹ terminal uridylation of viral RNAs as a conserved antiviral defense 41 
mechanism. 42 
 43 
RNA viruses are a major threat to human health and food security. Understanding the 44 
fundamental mechanisms by which animals and plants combat viral infections might lead to new 45 
therapeutic antiviral approaches. RNA interference (RNAi) is an important antiviral pathway in 46 
most animals and plants: Dicer recognizes and cleaves the double-stranded viral RNA genome 47 
into virus-derived small interfering RNAs (viral siRNAs, viRNAs), which are loaded into 48 
Argonaute proteins to form the RNA-induced silencing complex (RISC) that in turn targets the 49 
viral RNA genome 1. Vertebrates have additionally evolved a cellular signaling-based pathway, 50 
the interferon response (IR): upon recognition of foreign RNAs (i.e. double-stranded or bearing a 51 
5ʹ di/triphosphate), cytosolic receptors of the RIG-I family activate the IR which results in an 52 
antiviral state of the cell 2,3. In the evolutionary arms race between viruses and their hosts, 53 
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however, animals must have evolved a diverse range of antiviral strategies, to not solely rely on 54 
the RNAi or IR pathways.  55 
 56 
Here, we develop a system for antiviral gene discovery using the nematode 57 
Caenorhabditis elegans (C. elegans) and identify 3ʹ terminal uridylation of viral RNAs as a third 58 
antiviral mechanism in animals. 59 
 60 
RESULTS 61 
A forward genetic screen identifies new genes required for antiviral defense in C. elegans 62 
We carried out a forward genetic screen to discover antiviral pathways in animals using 63 
C. elegans and its natural intestinal pathogen, the Orsay virus (OrV) 4-12. OrV is a bipartite 64 
positive-strand RNA virus related to the Nodaviridae 4. As is typical for positive sense RNA 65 
viruses, the genomic strand of the OrV is a template for translation. The OrV spreads 66 
horizontally in populations of C. elegans: it is taken up orally, infects only intestinal cells and 67 
probably exits through defecation 4. While C. elegans lacks an interferon pathway, a RIG-I 68 
ortholog, DRH-1, acts in viral recognition. DRH-1 forms a Viral Recognition Complex (ViRC) 69 
with the C. elegans Dicer (DCR-1) and the RNA-binding protein RDE-4 to link viral recognition 70 
to a dedicated antiviral RNAi pathway, involving the Argonaute protein RDE-1 5,11,13,14. DRH-1 71 
also induces a transcriptional immune response through a STAT-dependent signaling pathway 72 
(e.g. the gene sdz-6, as shown by qRT-PCR in Extended Data Fig. 1a) 10,15,16. However, the 73 
antiviral function of the DRH-1-mediated stress response remains to be elucidated. C. elegans 74 
also elicits a “biotic stress response” upon OrV infection that is independent of DRH-1 and 75 
partially overlaps with transcriptional responses induced by other types of pathogens, possibly as 76 
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a result of perturbations in cell homeostasis and/or mechanical integrity (e.g. the gene lys-3, 77 
encoding an antibacterial enzyme, as shown by qRT-PCR in Extended Data Fig. 1a) 10. We 78 
generated a viral stress sensor transgene by placing the green fluorescent protein (GFP) under the 79 
control of the lys-3 promoter (allele mjIs228; Fig. 1a). Upon infection, the level of GFP 80 
expression in the intestine mirrored the viral load in wild type, drh-1 and rde-1 mutants 81 
(Extended Data Fig. 1b, c). We used chemical mutagenesis to screen ~50,000 haploid genomes 82 
(Fig. 1b) and identified 16 isolates we named Ovid (Orsay Virus Immune Deficient; Fig. 1c and 83 
Supplementary Table 1). 13 out of 16 ovid mutants showed increased viral loads (Fig. 1c). ovid-84 
3,4,5,10,12 are compromised in somatic RNAi, as tested by RNAi knockdown of the gene unc-85 
22, which normally results in impaired locomation (Fig. 1c), and ovid-3,4,10 carry new alleles of 86 
RNAi genes mut-16, rde-4 and rrf-1, respectively (Table 1). To further stratify our Ovid isolates, 87 
we assayed DRH-1 pathway activation using the expression of the downstream induced gene 88 
sdz-6 as readout (Fig. 1d). Only ovid-1 phenocopied drh-1 mutants and we subsequently 89 
demonstrated that ovid-1 defines a new allele of drh-1 (Fig. 1d). We identified a number of 90 
additional candidate genes (Table 1). ovid-9 and ovid-11 mutants are neither defective in 91 
canonical RNAi nor in the DRH-1 pathway and thus represent candidate genes for novel antiviral 92 
defense mechanisms. 93 
 94 
The terminal uridylyltransferase CDE-1 is required for antiviral defense in C. elegans 95 
Whole-genome re-sequencing and genetic complementation tests revealed the causative mutation 96 
in ovid-9 to be a single-nucleotide nonsense mutation in the cde-1 gene (mj414, glutamine 910 to 97 
STOP) (Fig. 2a and Extended Data Fig. 2). cde-1 encodes a catalytically active 3ʹ-terminal RNA 98 
uridylyltransferase (TUT), which is a homologue of mammalian TUT4 and TUT7 enzymes 17-19 99 
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(Fig. 2b, c). The independently derived cde-1 (tm1021) knockout strain also phenocopied viral 100 
stress sensor activation (Extended Data Fig. 3), high viral loads (Fig. 2d), and horizontal 101 
transmission of infection (Extended Data Fig. 3). RNA FISH revealed that viral infection is 102 
restricted to the intestine in cde-1 and in cde-1; drh-1 double mutants 4,9 (Extended Data Fig. 4a). 103 
We validated that CDE-1 is present in the intestine using a GFP fusion 18 (Extended Data Fig. 104 
4b). To disentangle between the functions of CDE-1 in different tissues, cde-1 was exclusively 105 
expressed from an intestine-specific vha-6p promoter (Extended Data Fig. 4c).  Animals with 106 
intestinal expression of cde-1 became resistant to viral infection (Extended Data Fig. 4d), but 107 
kept a defect in meiotic chromosome segregation (Extended Data Fig. 4e), probably caused by 108 
CDE-1 depletion in the germline 17. CDE-1 contains a conserved triad of acid aspartic residues 109 
(DDD) in its nucleotidyltransferase domain. Mutation of the corresponding DDD triad to DAD 110 
(D1011A) in human TUT4 resulted in loss of catalytic activity 20. A cde-1 DAD mutant strain 111 
(Fig. 2a,c) showed similar viral susceptibility as the cde-1 null mutants (Fig. 2d). In summary, 112 
we identify CDE-1-mediated 3ʹ terminal uridylation as an antiviral activity in the intestine of C. 113 
elegans. 114 
 115 
CDE-1 exert its antiviral function independently of antiviral RNAi 116 
In eukaryotes, addition of 3ʹ uridyl-tails (U-tails) by TUTs is a degradation signal that can 117 
engage: (i) the XRN-family of exoribonucleases for 5ʹ to 3ʹ RNA decay; (ii) the 3ʹ to 5ʹ 118 
exoribonuclease DIS3L2; (iii) the 3ʹ to 5ʹ exosome complex 21-24. We sought to identify the 119 
RNA(s) targeted by CDE-1 in its antiviral role. CDE-1 is implicated in endogenous RNAi 120 
pathways that are restricted to the germline 17. Small RNA sequencing on whole animals 121 
revealed that siRNAs are targeted by CDE-1 for 3ʹ uridylation, miRNAs are occasionally 122 
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targeted, and piRNAs are not targeted 17 (Extended Data Fig. 5a). The role of CDE-1 in small 123 
RNA function remains unclear as depletion of CDE-1 leads to only subtle changes in siRNA and 124 
miRNA steady state levels (Extended Data Fig. 5b, c). To understand if CDE-1 functions 125 
through modification of siRNAs in antiviral immunity, we tested cde-1 mutants directly for 126 
defects in antiviral RNAi. During an antiviral RNAi response in C. elegans, the ViRC complex 127 
recognizes the dsRNA of the replicating viral genome and dices it into sense and antisense ~23-128 
nt long primary viRNAs, which are loaded into the RDE-1 Argonaute protein 5 (Fig. 3a). The 129 
RNAi response is further amplified by RNA-dependent RNA polymerase (RdRP, RRF-1) 130 
generated 22-nt long antisense secondary viRNAs, with a 5ʹ triphosphate guanine (22G-RNAs), 131 
which are incorporated into secondary Argonaute proteins to silence viral amplification 5 (Fig. 132 
3a). Thus, in an animal with functional antiviral RNAi, a high viral load should correlate with a 133 
high level of viRNAs. We measured primary and secondary viRNAs in different genetic 134 
backgrounds (Fig. 3b,c). All the mutants tested (drh-1, rde-1, cde-1) accumulate high levels of 135 
the virus as compared to wild type. In drh-1 mutants, primary and secondary viRNAs are 136 
depleted when compared to wild type, despite the increase in viral load. In rde-1 mutants, 137 
primary viRNAs are abundant but secondary viRNAs are depleted, as in drh-1. In contrast, cde-1 138 
mutants accumulate both primary and secondary viRNAs to a level that correlates with the high 139 
viral load. To determine if viRNAs can silence viral amplification in cde-1 mutants, we carried 140 
out epistasis analysis using null mutants of drh-1, rde-1 and cde-1 (Fig. 3d,e). Both cde-1;drh-1 141 
and cde-1;rde-1 double mutants showed an increase in viral load as compared to drh-1 or rde-1 142 
on its own. We conclude that CDE-1 does not exert its immune function through the antiviral 143 
RNAi pathway. 144 
 145 
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CDE-1 defines a novel antiviral immunity pathway 146 
In mammals, uridylation is coupled to poly(A) tail length where TUT4 and TUT7 (collectively 147 
called TUT4(7)) preferentially uridylate mRNAs with short poly(A) tails (<25 nt) to facilitate 148 
their degradation 25,26 (Fig. 4a). We thus assessed the impact of CDE-1 on endogenous mRNA 149 
poly(A) tail lengths and terminal nucleotide addition in infected wild-type or cde-1 mutant 150 
animals using TAIL-seq 25,27. The C. elegans transcriptome revealed a bimodal distribution of 151 
poly(A) tail lengths, with a major peak of poly(A) tails of ~40 nt, and a second peak of poly(A) 152 
tails of ~10 nt (Fig. 4b; using our method we could not assess transcripts with poly(A) tails > 79 153 
nt). In cde-1 mutants, there is a shift of the major ~40 nt peak to ~36 nt and an increase in 154 
transcripts with shorter poly(A) (Fig. 4b). We infer that CDE-1 promotes the degradation of 155 
transcripts with short poly(A) tails in C. elegans too. However, CDE-1 had no global effect on 156 
the poly(A) tail distribution of OrV-induced stress response genes (Extended Data Fig. 6a). Also, 157 
the OrV-induced stress response was stronger in cde-1 mutants than in wild-type upon infection 158 
(Extended Data Fig. 6b), reflecting the difference in viral load between these two strains. This 159 
indicates that CDE-1 is not required for the OrV-induced stress response. Although we cannot 160 
formally rule out that CDE-1 may regulate an endogenous target(s), the evidence indicates this is 161 
not CDE-1’s principal function in antiviral immunity. 162 
 163 
Instead, we postulated that the viral RNA genome itself may be uridylated by CDE-1. U-tails can 164 
only be observed on a small percentage of cellular RNAs as uridylated RNAs are prone to be 165 
degraded 26. To detect uridylated Orsay RNA degradation intermediates, we carried out 3ʹ rapid 166 
amplification of cDNA ends (RACE) followed by high-throughput sequencing of the OrV RNAs 167 
extracted from C. elegans two days postinfection (RACE-seq; Extended Data Fig. 7a). Mono(U) 168 
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tails constituted the most abundant fraction of non-templated nucleotides detected at the 3ʹ end of 169 
both OrV RNA1 and OrV RNA2 (Fig. 4c-e). For both RNA1 and 2, U-tailing was lost in two 170 
independent cde-1 mutant alleles. In contrast, drh-1 and rde-1 mutants showed similar levels of 171 
viral RNA U-tails to wild-type, indicating that U-tailing is independent of viral load and that 172 
CDE-1 is not in limited quantities (Extended Data Fig. 7b,c). OrV RNA1 and RNA2 have a 173 
terminal uridylyl residue in their genome such that the addition of an extra non-templated uridine 174 
by CDE-1 forms a UU termination (Fig. 4d), which is a signal for uridylation-dependent RNA 175 
decay 21,23. The two XRN paralogs in C. elegans (XRN-1 and XRN-2) and the exosome 176 
components (e.g. DIS-3, EXOS-2) are essential 28,29, and these RNA degradation pathways 177 
normally act redundantly on uridylated RNAs 26. We therefore subjected C. elegans to a short 178 
(24 hours) RNAi treatment to effect a partial knockdown of cde-1, the exonuclease disl-2 (the C. 179 
elegans DIS3L2 homologue), the exosome components exos-2 and dis-3, and the exonuclease 180 
xrn-2. Treated animals, which appeared superficially wild type, were infected with OrV for 24 181 
hours. The frequency of U-tails in OrV RNA2 was measured by RACE-seq (Fig. 4f). ~4% of 182 
OrV RNA2 were uridylated in animals exposed to the empty vector control RNAi, compared to 183 
~1% in cde-1 knockdown. RNAi treatments against disl-2 did not affect the U-tail frequency. We 184 
measured a 1.4 to 1.7 fold increase in U-tail frequency upon RNAi treatment against exos-2, dis-185 
3 and xrn-2, suggesting that these factors each contribute to the degradation of uridylated viral 186 
RNAs, in accordance with a study that shows that DIS3 and the exosome can degrade viral 187 
RNAs in Drosophila and human cells 30. We conclude that C. elegans uses uridylation of the 188 
OrV as an innate immune defense. This mechanism acts in parallel to antiviral RNAi to combat 189 
viral infection (Fig. 5). 190 
 191 
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Terminal uridylyltransferases target viral RNAs in mammalian cells 192 
The U-tail modification is conserved in eukaryotes and could impact a broad range of viruses in 193 
a variety of hosts 31. We tested if U-tailing affects the replication of Influenza A virus (IAV), 194 
which can infect human and murine cells. The IAV genome consists of eight antisense RNA 195 
segments (viral RNAs, vRNAs) from which the viral RdRP produces: (i) the sense 196 
complementary RNAs (cRNAs), which serve as templates to produce more vRNAs; and (ii) the 197 
mRNAs that are 3ʹ polyadenylated and exported to the cytosol for translation into viral proteins 198 
32 (Fig. 6a). We examined the 3ʹ end of a set of IAV RNAs, at 8 hours post-infection (hpi), in 199 
A549 human lung cells by RACE-seq. We could not detect U-tails at the ends of vRNAs or 200 
cRNAs. In contrast, viral mRNAs were highly uridylated at their 3ʹ end, with ~77% of the IAV 201 
Nucleoprotein (NP) mRNA containing a U-tail, and a di(U)-tail being the most common type of 202 
3ʹ end (~32%) (Fig. 6b-e). The IAV NP mRNA is also uridylated (~40-50%) at 8 hpi in mouse 203 
embryonic fibroblasts (MEFs), but uridylation was lost in MEFs deficient in both Tut4 and Tut7 204 
25 (Fig. 6f). Thus TUT4(7) can uridylate the 3ʹ end of viral RNAs in mammalian cells. The 205 
RACE-seq can only detect IAV mRNAs with poly(A) tails of <70 nt; it is possible that some 206 
IAV mRNAs with very long poly(A) tails are less prone to be uridylated. To test the impact of 207 
TUT4(7) on IAV, we measured the quantity of NP mRNA by qRT-PCR in infected MEFs 208 
(Extended Data Fig. 8a). The IAV NP mRNA accumulated more rapidly and to a higher level at 209 
the peak in MEFs Tut4(7) KO cells (peak at 8 hpi) compared to WT cells (peak at 16 hpi) before 210 
decreasing later in infection (24 hpi). Consistent with the difference in mRNA levels, the NP 211 
mRNA-encoded viral nucleoprotein (NP) accumulated more rapidly in MEFs Tut4(7) KO cells 212 
compared to WT during the first eight hours of infection (Extended Data Fig. 8b). Accordingly, 213 
more infected cells overall were observed in MEFs Tut4(7) KO compared to WT (Fig. 6g). In 214 
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conclusion, TUT4(7) could act as an early barrier against IAV infection in mammalian cells. 215 
Although we cannot rule out that TUT4(7) may impact other steps of the IAV viral cycle, such as 216 
entry, our data strongly supports a model where TUT4(7) act by reducing the expression levels 217 
of IAV mRNAs during the early stages of IAV infection in MEFs, leading to a decrease in viral 218 
protein levels and rates of infection. Future studies will need to address the antiviral function of 219 
TUT4(7) in a variety of relevant host-virus models. 220 
 221 
DISCUSSION 222 
Previously, we have shown that the antiviral RNAi pathway and DRH-1 are central to the innate 223 
immune response of C. elegans 5. Here, we demonstrate that the terminal uridylyltransferases 224 
also play a critical role in antiviral immunity, uridylating viral RNAs (with 1-2 Us) to mark them 225 
for degradation. It is unclear how terminal uridylyltransferase recognize viral RNAs as bona fide 226 
targets. Receptors of the RIG-I family commonly recognize pathogen-associated patterns at the 227 
5ʹ termini of viral RNAs. In contrast, terminal uridylyltransferases interact with the 3ʹ termini of 228 
cytosolic RNAs with no poly(A)-tail or a short poly(A)-tail. As many RNA viruses, like OrV, 229 
lack a poly(A) tail at the 3ʹ termini of their RNA genomes, this may be a pathogen-associated 230 
pattern-recognition feature. We speculate that the IAV mRNAs and a fraction of the OrV RNAs 231 
are vulnerable to TUTs when exposed in the cytosol for translation. In conclusion, we find that 232 
terminal uridylyltransferases are potent antiviral factors during the early stages of RNA virus 233 
infections in C. elegans and in mammalian cells. This finding supports a scenario where 234 
eukaryotic mRNA decay pathways originally evolved as intrinsic cellular defenses against 235 
pathogens 33,34. Vertebrates also benefit from the interferon response and adaptive immune 236 
system, serving as potent lines of defense against pathogenic viruses; future studies will thus 237 
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need to address the relative importance of antiviral uridylation in whole organisms. Terminal 238 
uridylyltransferases are widely conserved in eukaryotes and could potentially target a wide range 239 
of RNA viruses 31. Perhaps as a response to this threat, some viruses evolved to protect their 240 
RNA termini, such as single-stranded RNA viruses of the Flaviviridae family, which have highly 241 
structured 3ʹ ends resistant to degradation by cellular exonucleases 35. Our study illustrates that 242 
the 3ʹ termini of viral RNAs are key in the evolutionary arms race between viruses and their 243 
hosts. 244 
 245 
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 325 
METHODS 326 
Genetics 327 
Animals were grown on agar plates, at 20°C, and fed with E. coli strain HB101 (obtained from 328 
the Caenorhabditis Genetics Center, University of Minnesota, USA). Standard C. elegans 329 
procedures were used for maintenance and genetic crosses 36. The wild-type strain refers to 330 
Bristol N2 unless stated otherwise. All strains used in this study are listed in the Supplementary 331 
Table 2. 332 
 333 
PCR primers 334 
All PCR primers used in this study are listed in the Supplementary Table 3. 335 
 336 
Viral filtrate preparation 337 
Viral filtrate was prepared as in 8. Briefly, JU1580 animals were first stably infected by the 338 
Orsay virus (OrV) in solid culture and then transferred in a liquid culture containing OP50 339 
bacteria for seven days. The liquid culture with infected JU1580 was then centrifuged at 16,000 340 
g for 30 min and the supernatant was filtered (0.22 µm filter) to produce the viral filtrate (stored 341 
at -80°C). 342 
 343 
Transgenesis of C. elegans with the lys-3p::GFP viral stress sensor 344 
The 452 bp region upstream of the lys-3 start codon and the first 57 bp of the coding region of 345 
lys-3 were used as a promoter and cloned into an entry clone using Multi-Site Gateway cloning 346 
(Invitrogen) according to manufacturer's instructions. The lys-3 donor plasmid was validated by 347 
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sequencing. Gateway technology was then used to clone the lys-3 fragment in frame with a GFP 348 
cDNA. The 3ʹ UTR of the tbb-2 (tubulin, beta) gene was used. The lys-3p::GFP:tbb-2-3ʹUTR 349 
plasmid was amplified and purified according to Invitrogen's instruction. The C. elegans 350 
microinjection mix was: 5 ng/µl plasmid lys-3p::GFP:tbb-2-3ʹUTR; 5 ng/µl co-injection marker 351 
(myo-2::mcherry::unc-54-3ʹUTR, pharynx expression) and 85 ng/µl 1 kb Invitrogen ladder in 1× 352 
injection buffer (20 mM potassium phosphate, 3 mM potassium citrate, pH 7.5). This mix was 353 
microinjected into the gonads of rde-1 (ne219) mutants to generate a multicopy 354 
extrachromosomal array (allele mjEx547). X-ray integration of the transgene into the C. elegans 355 
genome was performed as described previously 37. Animals carrying an integrated transgene 356 
(allele mjIs228) were outcrossed three times to generate SX2635 (lacking ne219), referred to as 357 
wild-type viral stress sensor strain in this study. 358 
 359 
Confocal images of the biostress reporter 360 
A 2% agar pad was used on top of a glass slide and a drop of 10 µM tetramisol in M9 medium 361 
was placed on this agar pad. Animals were picked into the tetramisol solution. Imaging was 362 
performed with an Olympus Upright FV1000 microscope at 10× or 20× magnification, as 363 
specified, using the FluoView image software (Olympus). Identical microscope settings were 364 
used for all images within a figure. 365 
 366 
Forward genetic screen for Ovid screen isolates 367 
Approximately 4,000 viral stress sensor transgenic animals were mutagenized using ethyl 368 
methanesulfonate (EMS) as described in 36 and 38. Approximately 50,000 F2 animals were 369 
infected for 3-4 days and ~2,000 animals showing intestinal GFP were picked individually for 370 
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re-testing. 16 F2 families showed transmission of the viral stress sensor activation. Bleach 371 
treatment confirmed that removing OrV lead to a loss of intestinal GFP signal. 372 
 373 
C. elegans infection by the Orsay virus 374 
Animals were either infected for four days as asynchronous populations or for two days as 375 
synchronous populations. Infections of asynchronous populations were performed as in 5. 376 
Briefly, two L4 hermaphrodites were distributed in each 50 mm plates and, on the next day, 20 377 
µl of viral filtrate was spread on the plates. Animals were harvested (for viral load measurement) 378 
or observed under a Leica M165 FC fluorescent microscope (for scoring of the viral stress 379 
sensor) four days post-infection (4 dpi). This method was typically used for the characterization 380 
of the Ovid screen isolates. For the infection of synchronous populations, 200 animals at the 381 
larval stage L1 were deposited on each 50 mm plate. On the next day, L2 animals were infected 382 
with 20 µl of viral filtrate homogeneously spread on the plate. Plates were kept up-side-up for 24 383 
hrs. Animals were harvested for viral load measurement at 2 dpi. This method was used to 384 
measure the viral load in cde-1 mutants, as indicated in the figure legends. 385 
 386 
RNA level measurement by qRT-PCR 387 
Harvested animals were washed three times by pelleting-resuspension in M9 solution. Lysis and 388 
qRT-PCR was then performed from 5 µl of animal pellet using the Power SYBR Green Cells-to-389 
Ct kit (Ambion, Austin, TX) as described in 5. The primers M1835 and M1836 13, and M4410 390 
and M4411 4, were used to measure RNA levels of gapdh and OrV gRNA1, respectively. 391 
 392 
RNAi-mediated knockdown of unc-22 393 
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All the bacterial feeding clones used in this study were a kind gift from the laboratory of Julie 394 
Ahringer. Bacteria were grown in LB-Ampicillin (50 μg/ml) for 6 hrs, then seeded onto 50 mm 395 
NGM agar plates containing 1 mM IPTG and 25 μg/ml Carbenicillin at a volume of 300 μl 396 
bacterial culture per plate and left to dry at room temperature, protected from the light, for 48 397 
hrs. Two L4 animals were picked onto each RNAi plates and the young adult progeny were 398 
scored for the phenotype of interest after five days. 399 
 400 
Transgenesis of C. elegans with the CDE-1::GFP fosmid and imaging 401 
The modified fosmid WRM064A_D06 where the GFP sequence is added at the N-terminal end 402 
of cde-1 was provided by the TransgeneOme Project (Max Planck Institute of Molecular Cell 403 
Biology and Genetics, TransgeneOme Unit, Pfotenhauerstr. 108, 01307 Dresden, Germany; 404 
construct 09318202437763223 H08) 39. The construct was injected into the gonad of N2 animals 405 
to produce an extrachromosomal array (as described for the biostress reporter), using a myo-406 
3p::mCherry::unc-54-3′UTR construct as a co-injection reporter. Transgenic animals (strain 407 
SX3123; allele mjEx594) were imaged with an Olympus Upright FV1000 microscope at 10x 408 
magnification. 409 
 410 
Fluorescence in situ hybridization of the Orsay virus RNA2 411 
Animals were harvested in 15 ml of nanopure water and washed three times by pelleting-412 
resuspension in nanopure water. Animals were then transferred to 1.5 ml tubes with a glass 413 
pipette. 1 ml of fixative solution (4% formaldehyde in 1X PBS) was added and samples were 414 
incubating at room temperature, on a rotating wheel, for 45 min. Nematodes were then washed 415 
twice by pelleting-resuspension in 1 ml of 1x PBS. Pellet of animals was resuspended in 1 ml 416 
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70% ethanol and stored at 4°C. After removal of the ethanol, fixed nematodes were washed once 417 
in 1 ml of wash solution (10% formamide, 2X SSC). The animal pellet was resuspended in 100 418 
µl of hybridization solution (10% dextran sulfate, 2X SSC, 10% formamide) with 1 µl 1:50 of 419 
the probe v1580-RNA2-TexRed (ACCATGCGAGCATTCTGAACGTCA), a kind gift of Marie-420 
Anne Félix, and incubated overnight at 30°C protected from the light. The next day, animals 421 
were washed three times in wash solution by pelleting-resuspension. Eventually, animals were 422 
resuspended in 1 ml wash solution with DAPI and incubated at 30°C for 30 min. Samples were 423 
centrifuged and supernatant was discarded. The animal pellet was resuspended in 1 ml of 2X 424 
SSC solution and stored at 4°C protected from light. Animals were then placed on a glass slide, 425 
in a drop of Vectashield anti-fade solution (Vector). Imaging was performed on an Olympus 426 
Upright FV1000 at 40x magnification, using the FluoView image software (Olympus). Same 427 
settings of fluorescence were used for all images compared. 428 
Transgenesis of C. elegans with the vha-6p::gfp plasmid and viral load measurement 429 
The 878 bp region upstream of the vha-6 start codon was used as a promoter and cloned into an 430 
entry clone using Multi-Site Gateway cloning (Invitrogen) according to manufacturer's 431 
instructions. The vha-6p donor plasmid was validated by sequencing. Gateway technology was 432 
then used to clone the vha-6p upstream of (i) the GFP cDNA, or (ii) the full length cde-1 gene 433 
(from ATG to STOP with endogenous introns). The 3ʹ UTR of the tbb-2 (tubulin, beta) gene was 434 
used. The vha-6p::GFP::tbb-2-3ʹUTR and vha-6p::cde-1::tbb-2-3ʹUTR plasmids were amplified 435 
and purified according to Invitrogen's instruction. The C. elegans microinjection mix was: 10 436 
ng/µl plasmid vha-6p::GFP:tbb-2-3ʹUTR; 10 ng/µl plasmid vha-6p::cde-1::tbb-2-3ʹUTR; 5 ng/µl 437 
co-injection marker (myo-2::mcherry::unc-54-3ʹUTR, pharynx expression) and 75 ng/µl 1 kb 438 
Invitrogen ladder in 1× injection buffer (20 mM potassium phosphate, 3 mM potassium citrate, 439 
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pH 7.5). This mix was microinjected into the gonads of cde-1 (tm1021) mutants to generate a 440 
multicopy extrachromosomal array (allele mjEx595). vha-6p driven GFP expression was only 441 
observed in the intestine. 100 animals carrying the extrachromosomal array were manually 442 
selected for infection (from the L2 larval stage to young adult). 443 
 444 
Small RNA sequencing 445 
Small RNA libraries were prepared from infected animals as previously described in 5. We used 446 
pellets of animals, washed three times in M9 solution and resuspended in 1 ml of TriSure 447 
(Bioline) as a starting material. RNA extraction was performed according to manufacturer’s 448 
instructions. Some populations of siRNAs (including secondary viRNAs) contain a characteristic 449 
5ʹ triphosphate group that has to be replaced by a 5ʹ monophosphate to allow the 5ʹ ligation step 450 
of the library preparation. For this purpose, 1 µg of RNA was put in solution with 1X 5ʹp 451 
polyphophatase buffer and 1 µl of 5ʹ polyphophatase (Epicentre) for a total volume of 20 µl, 452 
incubated for 30 min at 37°C and then submitted to phenol purification and resuspended in 5 µl 453 
of nuclease-free water. Treated RNA sample was entirely used as starting material for the 454 
TruSeq Small RNA kit (Illumina), following the manufacturer’s instructions, to make the so-455 
called 5ʹ independent libraries. So-called 5ʹ dependent libraries were made by a similar procedure 456 
but without polyphophatase treatment, so that only 5ʹ monophosphate siRNAs (such as primary 457 
viRNAs) could be cloned. Libraries were submitted to the Gurdon Institute sequencing facility 458 
for Illumina HiSeq sequencing (SR36). Small RNA sequencing data was aligned to the Ensemble 459 
WBcel235 release of the C. elegans genome using STAR 40 (v2.5.1b). Briefly, the aligner will 460 
allow untemplated residues at the ends of an aligned sequence when run in local mode. 461 
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Untemplated 3ʹ sequences were extracted and analysed using custom Python scripts. Details of 462 
the analyses for each small RNA subtype can be found in the source code. For miRNA 463 
differential expression, reads were counted against the miRBase miRNA annotations 464 
(miRBase21 hairpins, WBcel235 genome) using featureCounts 41 (v1.5.0-p1). Differential 465 
expression analysis was performed on the counts using DESeq2 42 (v1.10.1). 466 
 467 
CRISPR/Cas9 for cde-1 catalytic dead mutant 468 
A CRISPR/Cas9-mediated mutation of cde-1 was generated as previously described 43. Guide 469 
RNA: UUUGCUGUCAAAUCCUUUGG. Homologous recombination template: 470 
TCAGCTATTGCTATTTGTTTGAGATTCGGAGATGGAGATGTTCCGCCTAAAGACTTG471 
ACAGCAAAAGAAGTTATTCAGAAAACTGAATCCGTTCTCAGAAAATGTCATTT. Only 472 
the D1069A missense mutation was introduced, as verified by sequencing. 473 
 474 
TAIL-seq 475 
The TAIL-seq was performed as previously described in 27. Tail-seq libraries were processed 476 
using Tailseeker 2 27. The 5ʹ and 3ʹ libraries were subsequently adapter trimmed using cutadapt 477 
1.10 44 with Illumina small RNA-seq adapters and filtered to a minimum length of 5bp. Trimmed 478 
5ʹ reads were mapped with STAR 2.5.2a 40 against a combined meta-genome consisting of the 479 
C. elegans reference genome WBcel235 45 and the OrV genome 4. Mapping was performed in 480 
end-to-end mode allowing no mismatches and a gap opening and extension penalty of 10,000. 481 
Reads were assigned to genes with bedtools 2.26.0 46. Subsequently, 3ʹ reads without poly(A) tail 482 
or too many dark cycles were removed from the data. For the subsequent analysis, all C. elegans 483 
tags with poly(A) tail length equal to zero were discarded. Average poly(A) tail lengths and 484 
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uridylation lengths for each sample were calculated as the arithmetic mean weighted by the 485 
support for each tag, reported by Tailseeker 2. The complete code is at 486 
https://github.com/klmr/poly-u/tree/submitted. 487 
 488 
mRNA libraries for deep sequencing 489 
mRNA libraries were prepared from three independent infections, using the NEBNext 490 
Ultra RNA non-directional Library kit with poly(A) selection (NEB), according to 491 
manufacturer’s instructions. Libraries were submitted to the Gurdon Institute sequencing facility 492 
for Illumina HiSeq sequencing (SR30). Differentially expressed genes were then called using 493 
EdgeR 47.  494 
 495 
3ʹ RACE-seq on the Orsay virus RNAs 496 
The 3ʹ RACE was performed on the same RNA input than that used for small RNA libraries, 497 
without polyphosphatase treatment. 200 ng of RNA were submitted to 3ʹ ligation using the 498 
TruSeq Small RNA kit (Illumina), following the manufacturer’s instructions. 3ʹ ligated RNA was 499 
used for reverse-transcription, still using the TruSeq Small RNA kit whilst bypassing the 5ʹ 500 
ligation step. The 3ʹ end of OrV RNA1 (or RNA2) genome was amplified by PCR (“PCR1”) 501 
from 2 µl of cDNA, using the primers M7454 and M7456 (or M7455 and M7456) and the 502 
Phusion High-Fidelity Taq Polymerase (NEB) with CG buffer, according to manufacturer's 503 
instructions. The thermocyler was programmed to 30 seconds at 98°C; 15 cycles of 5 seconds at 504 
98 °C followed by 20 seconds at 60°C and 10 seconds at 72°C. The 5ʹ adapter sequence from the 505 
TruSeq Small RNA kit was then introduced at the 5ʹ end of the amplicons by PCR (“PCR2”) 506 
using the primers M7456 and M7601 for OrV RNA1 (or M7456 and M7602 for the OrV RNA2), 507 
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using 2 µl of 1/10 diluted amplicon from PCR1 as a template and the same PCR conditions than 508 
that used in PCR1. The amplicons from PCR2 were purified using the DNA Clean & 509 
Concentrator-5 kit (Zymo Research) and resuspended in 10 µl of water. Resulting DNA was 510 
used as an input for the PCR amplification step of the TruSeq Small RNA kit, following the 511 
manufacturer’s instructions. Libraries were submitted to the Gurdon Institute sequencing facility 512 
for Illumina HiSeq sequencing (PE100). The libraries were run on a 10% polyacrylamide gel for 513 
size selection (the amplicons could be visualized under UV light and the bands were cut at the 514 
same distance of migration for all samples). Paired-end reads obtained from the 3ʹ RACE 515 
experiment on the viral genome show overlap. The PEAR software 48 was used to merge the 516 
paired reads into a single read (v0.9.6, default parameters). Merged reads not starting with the 517 
targeted 3ʹ viral genome sequence fragment were discarded. The targeted viral genome sequence 518 
was removed from the remaining reads using custom python scripts 519 
(https://github.com/tdido/cde-1_analysis). The resulting sequences representing the untemplated 520 
tails were analyzed using custom python scripts. 521 
 522 
RNAi-mediated knockdown of exonucleases 523 
Synchronized animals were grown on normal HB101 food until the L2 larval stage and then 524 
transferred RNAi food. Animals were left on RNAi plate (24 hours prior to infection) and 525 
infected for 24 hours, from the old L3/young L4 larval stages to adult. RACEseq was performed 526 
as described above. 527 
 528 
Cell culture  529 
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MEF cells were cultured with DMEM (GIBECO) supplemented with 12.5% FBS, 2mM L-530 
glutamine, non-essential amino acid,100 units/ml penicillin/streptomycin, 100 uM β-531 
mercaptoethanol (Sigma). Cells were splitted 1:4 and passaged every three days. A549 cells were 532 
cultured with DMEM (GIBECO) supplemented with 10% FBS, 2mM L-glutamine, non-essential 533 
amino acid,100 units/ml penicillin/streptomycin and 25mM HEPES. 534 
 535 
Cell lines used in this study 536 
All cell lines were tested for negative for mycoplasma. Tut4(7) CTR and KO MEFs were derived 537 
from E13.5 embryos from crosses of Tut4+/fl;Tut7+/fl;R26+/+ and Tut4+/fl;Tut7+/fl;R26ERT-cre/ERT-538 
cre mice by standard procedures and immortalized at passage 2 by two consecutive infections 539 
with pBabeSV40LT. Cre-mediated deletion to obtain Tut4(7) null alleles was induced with 600 540 
nM 4-hydroxytamoxifen for three days 25. All mice used in this study were bred and maintained 541 
in EMBL Mouse Biology Unit, Monterotondo, and subsequently in the Centre for Regenerative 542 
Medicine, Edinburgh. All procedures were done in accordance to the current Italian legislation 543 
(Art. 9, 27. Jan 1992, nu116) under license from the Italian health ministry or the UK Home 544 
Office regulations, respectively. 545 
 546 
A549 and MEF cells infection by Influenza A virus and RACE-seq  547 
Influenza A virus (A/WSN/1933, H1N1) used in this study was titrated on MDCK cells. All the 548 
inoculation MOI of influenza A virus described here and below was calculated as an equivalent 549 
MOI on the originally titrated MDCK cells. 550 
A549 or MEF cells were trypsinized and seeded as 2X10^6 cells per T25 flask one day before 551 
infection. 16 hours after seeding, culture media were removed and cells were washed once with 552 
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pre-warmed DMEM. Influenza A virus (A/WSN/1933, H1N1) were inoculated at MOI 3 diluted 553 
with 1000 µl DMEM supplemented with 0.1% BSA (D0.1B). Cells were trypsinized and 554 
collected 8 hours post infection. 750 µl TRIzol were added into each infected sample and were 555 
then freezed at -80 °C. RNA extraction was performed according to the standard TRIzol 556 
procedure. 557 
For the A549 RACE-seq, 2 µg of RNA were submitted to 3ʹ ligation using the TruSeq Small 558 
RNA kit (Illumina), following the manufacturer’s instructions. 3ʹ ligated RNA was used for 559 
reverse-transcription, still using the TruSeq Small RNA kit (except that the Invitrogen 560 
Suprescript III was used instead of the Superscript II) whilst bypassing the 5ʹ ligation step. The 561 
RT final volume was 12.5 µl. After the RT, water was added to the samples to reach 18.5 µl, 562 
final volume. The 3ʹ end of IAV RNAs were amplified by PCR (“PCR1”) from 2 µl of cDNA, 563 
using the left primers M8443, M8444, M8451, M8452, M8453, M8454, M8455, M8456 564 
(depending on the target, see the Supplementary Table 3) with the right primer M7456 and the 565 
NEB Q5 polymerase, according to manufacturer's instructions (25 µl reaction). The thermocyler 566 
was programmed to 30 seconds at 98°C; 5 cycles of 5 seconds at 98 °C followed by 20 seconds 567 
at 60°C and 20 seconds at 72°C. Each PCR product was purified using the DNA Clean & 568 
Concentrator-5 kit (Zymo Research) and eluted in 11 µl of water. The 5ʹ adapter sequence from 569 
the TruSeq Small RNA kit was then introduced at the 5ʹ end of the amplicons by PCR (“PCR2”) 570 
using the left primers M8459, M8460, M8467, M8468, M8469, M8470, M8471, M8472 571 
(depending on the target, see the Supplementary Table 3) with the right primer M7601, using 10 572 
µl of purified PCR1 amplicon as a template and the same PCR conditions that used in PCR1. 573 
Again, the amplicons from PCR2 were purified using the Zymo columns and eluted in 11 µl of 574 
water. Resulting DNA was used as an input for the PCR amplification step of the TruSeq Small 575 
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RNA kit, following the manufacturer’s instructions. Libraries were submitted to the Gurdon 576 
Institute sequencing facility for Illumina HiSeq sequencing (PE100). The libraries were run on a 577 
10% polyacrylamide gel for size selection (the amplicons could be visualized under UV light and 578 
the bands were cut at the same distance of migration for all samples). Paired-end reads obtained 579 
from the 3ʹ RACE experiment on the viral genome show overlap. The PEAR software 48 was 580 
used to merge the paired reads into a single read (v0.9.6, default parameters). Merged reads not 581 
starting with the targeted 3ʹ viral RNA sequence fragment were discarded. The targeted viral 582 
genome sequence was removed from the remaining reads using custom python scripts 583 
(https://github.com/tdido/cde-1_analysis). The resulting sequences representing the untemplated 584 
tails were analyzed using custom python scripts. The MEFs RACE-seq was identical to the A549 585 
cells RACE-seq, except: (i) the starting material was 1 µg, (ii) the Invitrogen Superscript II was 586 
used for the RT, (iii) PCR1 and PCR2 had 10 cycles each. 587 
 588 
MEFs infection by Influenza A virus and qRT-PCR 589 
MEF cells were trypsinized and seeded as 8X10^4 cells per well of 24-well plate one day before 590 
infection. 16 hours after seeding, culture media were removed and cells were washed once with 591 
pre-warmed DMEM. Influenza A virus (A/WSN/1933, H1N1) were inoculated at MOI 3 diluted 592 
with 250 ul DMEM supplemented with 0.1% BSA (D0.1B). Cells were trypsinized and collected 593 
8, 16 and 24 hours post infection. 350 ul TRIzol were added into each infected sample. RNA was 594 
extracted using Direct-zol™ RNA MiniPrep (Zymo Research) purification according to the 595 
manufacture’s protocol and was finally eluted into 60 ul RNase/DNase free water.  The extracted 596 
RNA was subjected to strand specific qRT-PCR to quantify influenza virus replication as 597 
described in 49. 598 
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 599 
MEFs infection by Influenza A virus and FACS assay 600 
MEF cells were trypsinized and seeded as 1X10^4 cells per well of 96-well plate one day before 601 
infection. 16 hours after seeding, culture media were removed and cells were washed once with 602 
pre-warmed DMEM. Influenza A virus (A/WSN/1933, H1N1) were inoculated at MOI 3 diluted 603 
with 50 µl DMEM supplemented with 0.1% BSA (D0.1B).  Inoculum was removed after 1 hour 604 
of incubation at 37 °C. The infected cells were cultured with MEF cell culture medium with 605 
2.5% FBS. 8 hours post inoculation, culture media were removed and cells were trypsinized 606 
through incubation with 30 µl 0.05% trypsin for 3 minutes at 37 °C. Trypsinized cells were 607 
resuspended with 70ul of P2F (PBS with 2% FBS) and then fixed with 100 µl 4% PFA for 15 608 
minutes. Fixed cells were centrifuged at 300g for 5 minutes and then washed once with 100 µl 609 
P2F. Cells were then permeablized with buffer (0.1% Saponin, 10mM HEPES, 0.025% Sodium 610 
Azide in 1XHBSS) for 15 minutes at room temperature and then spinned at 500g for 2 minutes 611 
to remove buffer. Primary anti-influenza A virus nucleoprotein antibodies were purchased from 612 
Millipore (MAB8258B | clone A3, biotin-conjugated). The primary antibodies were diluted 613 
1:2000 in permeable buffer and 50 µl diluted antibodies were added into each well of 96-well 614 
plate. Primary antibodies were incubated with infected cells at room temperature for 1 hour. The 615 
cells were then washed 3 times with permeable buffer. FITC conjugated goat anti-mouse 616 
secondary antibodies were purchased from Invitrogen and diluted at 1:1000 in permeable buffer. 617 
Secondary antibodies were incubated for 1 hour at room temperature and washed as described 618 
before. The stained cells were finally resuspended in 70 µl P2F. The cell suspension was run on a 619 
high throughput FACS machine (MACSQuant® analyzer 10 - Miltenyi Biotec). Uninfected cells 620 
were stained the same as infected cells and were used as negative staining cell populations. Any 621 
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cells/events that had fluorescence intensity higher than all the negative staining cell population 622 
were gated as virus infection positive. Data were analyzed using flowjo software (version 10). 623 
 624 
Statistics and reproducibility 625 
Statistics as shown in the figure legends. Table 1: ovid-9 data was reproduced in an independent 626 
experiment, data on other Ovid isolates only produced in the shown experiment. ovid-9 GFP and 627 
RNAi scoring not blinded but reproduced by different authors. Fig. 1: ovid-9 data was 628 
reproduced in an independent experiment, data on other Ovid isolates only produced in the 629 
shown experiment. Paralyzed animals were not moving even after tapping the plate. Twitching 630 
animals were moving but distinctively twitching laterally. Fig. 2: reproduced in an independent 631 
experiment (except for the DAD catalityc mutant, only produced in the shown experiment). Fig. 632 
3: reproduced in an independent experiment. Fig. 4b: only produced in the shown experiment. 633 
Fig. 4d,e: reproduced in an independent experiment. Fig. 4f: only produced in the shown 634 
experiment. Fig. 6b,f: only produced in the shown experiment. Figure 6g: reproduced in an 635 
independent experiment. Supp. Fig. 1a: only produced in the shown experiment, corroborates 636 
published data as cited in the text. Supp. Fig. 1b: at least two pictures taken by condition, except 637 
for the male for which the only picture available is shown in the manuscript, all phenotypes 638 
(including in males) were observed multiple times. Supp. Fig. 2: reproduced in an independent 639 
experiment but with 28 F4 families instead of 64 F8 families. Not blinded but reproduced by 640 
different authors. Supp. Fig. 3: only produced in the shown experiment. Not blinded. Supp. Fig. 641 
4a: only produced in the shown experiment, at least two pictures per condition. Supp. Fig. 4b: 642 
only produced in the shown experiment, at least two pictures per condition, corroborates 643 
published data as cited in the text. Supp. Fig. 4d,e: only produced in the shown experiment. 644 
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Supp. Fig. 5a-c: only produced in the shown experiment, corroborates published data as cited in 645 
the text. Supp. Fig. 6a,b: only produced in the shown experiment. Supp. Fig. 7: reproduced in an 646 
independent experiment. Supp. Fig. 8: reproduced in an independent experiment. 647 
 648 
Data availability statement 649 
All raw sequencing data are deposited in GEO (small RNA sequencing: GSE80169; mRNA 650 
sequencing: GSE76901; TAILseq: GSE85893). All C. elegans strains created in this study will 651 
be freely available on a non-collaborative basis. Correspondence and requests for materials 652 
should be addressed to E.A.M. (eam29@cam.ac.uk). 653 
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TABLES 709 
Table 1 |  Ovid screen candidate genes 710 
Genotype High 
viral 
load? 
RNAi 
intact? 
High 
sdz-6 
level? 
Candidate 
gene 
Candidate 
variation 
Brief description 
WT No Yes Yes    
rde-1 Yes No Yes   RNAi factor 
  Le Pen et al., page 32 of 36 
drh-1 Yes Yes No   Viral RNA receptor 
ovid-1 Yes Yes No drh-1 Glu834Lys Viral RNA receptor 
ovid-2 Yes Yes Yes n.d.   
ovid-3 Yes No Yes mut-16 Gln861* RNAi factor 
ovid-4 Yes No Yes rde-4 Ala220Thr  RNAi factor 
ovid-5 Yes No Yes n.d.   
ovid-6 Yes Yes Yes T09B4.2 Pro330Leu Putative rho guanine 
nucleotide exchange 
factor 
ovid-7 Yes Yes Yes C41D11.6 Gly596Ser Putative RNA 
nuclease 
ovid-8 Yes Yes Yes n.d.   
ovid-9 Yes Yes Yes cde-1 Gln910*  Terminal 
uridylyltransferase 
ovid-10 Yes No Yes rrf-1 Gly45Glu RNAi factor 
ovid-11 Yes Yes Yes C54D10.14 Gly122Arg Uncharacterized, 
DRH-1-dependent 
induction 
ovid-12 Yes No Yes F27D4.6 Arg717* Uncharacterized 
ovid-13 n.s. Yes Yes n.d.   
ovid-14 n.s. Yes Yes n.d.   
ovid-15 n.s. Yes Yes n.d.   
ovid-16 Yes Yes Yes phi-32 
ssl-1 
Pro75Ser 
Gly1119Glu 
Ubiquitin gene 
SNF2-related 
n.s., not scored. n.d., not determined. 711 
 712 
FIGURES 713 
Figure 1 | A forward genetic screen identifies novel antiviral immunity genes 714 
a, Diagram of the lys-3p::gfp viral stress sensor. 715 
b, Ovid screen workflow. Transgenic animals carrying the viral stress sensor were mutagenized 716 
using EMS and F2 progeny were assayed. OrV, Orsay virus. Ovid, Orsay virus immunodeficient. 717 
  Le Pen et al., page 33 of 36 
c, Top panel: viral load of strains as indicated, measured by qRT-PCR of OrV RNA1, 4 dpi. Bars 718 
represent average value; error bars represent the standard error of the mean (SEM) of four 719 
independent infections. One-tailed student’s t-test: ****p<0.0001, *** p<0.001, **p<0.01, 720 
*p<0.05. Bottom panel: locomotion defects scored (paralyzed or twitching) after unc-22 RNAi 721 
feeding. Bars: average value; error: SEM; three independent RNAi treatments. Two-tailed 722 
student’s t-test: ****p<0.0001, **p<0.01. 723 
d, Viral load compared to sdz-6 mRNA levels by qRT-PCR. Dots: average value; error: SEM; 724 
four independent infections. Samples as in c. 725 
 726 
Figure 2 | The terminal uridylyltransferase CDE-1 restricts viral infection 727 
a, Diagram of cde-1 alleles. DAD, catalytic dead mutant. 728 
b, Neighbor joining tree of the terminal uridylyl transferases (TUTs) of C. elegans and humans 729 
and S. pombe CID1. 730 
c, Diagrams of C. elegans CDE-1 and human TUT4 and TUT7. Domains were predicted by 731 
Interpro. The central D of the conserved DDD catalytic triad is highlighted in red. 732 
d, Viral load as measured by qRT-PCR of OrV RNA1 genome in adults two days after infection. 733 
Boxplots: whiskers from minimum to maximum; dots: independent infection; n=5. One-tailed 734 
student’s t-test: **** p<0.0001, **p<0.01 735 
 736 
Figure 3 | CDE-1 acts in parallel to antiviral RNAi 737 
a, Schematic of antiviral RNAi in C. elegans. Viral Recognition Complex (ViRC) includes 738 
DCR-1; DRH-1; RDE-4. 739 
  Le Pen et al., page 34 of 36 
b, Comparison between the viral load and primary viRNA populations. Primary viRNAs (23-740 
nucleotide long, from 5ʹ monophosphate RNA sequencing). Only antisense RNAs were 741 
considered to exclude potential viral genome degradation products. Dots: independent infection. 742 
c, Comparison between the viral load and secondary viRNA populations. Secondary viRNAs 743 
(22-nucleotide long, starting with a G, from 5ʹ tri/monophosphate RNA sequencing). Samples as 744 
in b. 745 
d and e, Viral load as measured by qRT-PCR of OrV RNA1 genome in adults two days after 746 
infection. Boxplots: whiskers from minimum to maximum; dots: independent infection; n=5. 747 
One-tailed student’s t-test: *** p<0.001, **p<0.01, *p<0.05. Samples as in b. 748 
 749 
Figure 4 | CDE-1 directly targets the Orsay virus RNA genome for uridylation 750 
a, Schematic of TUT-mediated RNA degradation. 751 
b, Poly(A) tail length distribution measured by TAIL-seq after two days of OrV infection. 752 
Vertical bars: range from minimum to maximum (two independent C. elegans culture plates). 753 
Vertical grey line represents the mean of cde-1 and wild type peaks (38 nt). 754 
c, Schematic of Orsay virus replication 755 
d, Most frequent collapsed reads after RACE-seq on OrV RNA1 and RNA2 (2 dpi), respectively. 756 
Non-templated residues (absent from the reference genome) are indicated in red. 757 
e, Percentage reads with non-templated nucleotides detected at the 3ʹ end of OrV RNA1-2 in 758 
strains as indicated, two days post infection. Two independent infections per genotype. 759 
f, Percentage reads with a non-templated mono-uridyl residue at the 3ʹ end of OrV RNA2, upon 760 
RNAi-mediated gene knockdown as indicated, one day post infection. Bars; average; dots: 761 
independent RNAi treatments and infections. 762 
  Le Pen et al., page 35 of 36 
 763 
Figure 5 | Antiviral RNAi and virus terminal uridylation are parallel immune defense 764 
pathways in C. elegans. Virion cartoon adapted from 12. The Orsay virus primarily infects 765 
intestinal cells in C. elegans9. Once entered in the host cell, the virus disassembles in the 766 
cytoplasm and exposes its RNA genome. The Orsay virus has a bipartite positive-stand RNA 767 
genome that can be directly translated by the cellular machinery. The Orsay RNA1 molecule 768 
encodes a viral RNA dependent RNA polymerase (RdRP) and the Orsay RNA2 molecule 769 
encodes the capsid protein4. Virus amplification occurs in the cytoplasm in two steps: (i) the 770 
positive-strand genome serves as a template for the synthesis of a negative strand antigenome by 771 
the viral RdRP; (ii) the antigenome serves, in turn, as a template for further synthesis of genomic 772 
RNAs. The C. elegans antiviral RNAi response is initiated by DCR-1–DRH-1–RDE-4 (Viral 773 
RNA Recognition Complex) that recognize replicating double-stranded viral RNAs and process 774 
them into virus-derived small interfering RNAs (primary viRNAs). Primary viRNAs are loaded 775 
into the RDE-1 Argonaute protein and trigger the synthesis of secondary viRNAs by the host 776 
RdRP RRF-1, that uses the viral RNA as a template. Secondary viRNAs, loaded into somatic 777 
Argonaute proteins (SAGOs), target viral RNAs by base complementarity and potently reduce 778 
virus replication5,11. Viral RNAs are also targeted by the terminal uridylyltransferase CDE-1. 779 
CDE-1 marks viral RNAs with a 3ʹ U-tail to recruit 5ʹ to 3ʹ exonucleases of the XRN family, and 780 
3ʹ to 5ʹ exonucleases of the exosome complex. C. elegans may have additional antiviral 781 
pathways, for example a set of stress response genes is induced by a STAT signaling pathway 782 
upon virus infection, that could promote virus clearance (not shown in this model) 15,16. 783 
  784 
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Figure 6 | The terminal uridylyltransferases TUT4(7) attenuate Influenza A mRNAs in 785 
mammalian cells 786 
a, Schematic of Influenza A virus replication 787 
b-d, Most frequent collapsed reads after RACE-seq on IAV NP cRNA, NP vRNA and NP 788 
mRNA, respectively in A549 cells at 8 hpi. 789 
e, Percentage of reads with a non-templated U-tail (no U-tail; 1 U; 2 Us or ≥ 3 Us) in different 790 
RNAs as indicated measured by RACE-seq in A549 cells 8 hpi. 791 
f, Percentage of reads with a non-templated U-tail (as in e) in MEF cells of different genotypes 792 
as indicated (with two independently created cell lines per genotype). 793 
g-h, Percentage of infected cells measured by immunofluorescence against NP (FACS). Bars: 794 
average; Error: SEM; three independent infections. MEFs Tut4(7) KO are full null independent 795 
lines. 796 
 797 
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Supplementary Figure 1 
The viral stress sensor (lys-3p::GFP) is constitutively active in some tissues  but is induced in the intestine upon severe viral
infection. 
a, Comparison of viral load and the lys-3 and sdz-6 mRNA expression after two days of infection by qRT-
PCR, strains as indicated. Dots: independent infection. Samples as in Fig. 3d,e. 
 
 
b, Representative confocal sections (10× or 20× magnification, as specified) of the viral stress sensor in
wild type and drh-1 mutants without infection. The viral stress sensor exhibited constitutive activity in
uninfected individuals, which was restricted to specific tissues. GFP was observed at all developmental
stages in the pharynx and the rectum of hermaphrodites. Additionally, hermaphrodites at the L4 larval 
stage would show a strong GFP signal around the vulva and gravid adults exhibited the GFP in the uterine
lumen. In males, GFP was observed in the pharynx and the tail. GFP expression was comparable in wild
type and drh-1 mutants and independent of viral infection. Thus, the gene lys-3 is constitutively active in
tissues neighboring openings exposed to the environment, the most likely entry points of potential
bacterial pathogens. 
c, Representative confocal sections (20× magnification) of young adults (strains as indicated) carrying
the viral stress sensor. Animals were uninfected (mock) or infected with OrV for four days. The viral
stress sensor was strongly induced in the intestine after infection of drh-1 mutants, which is in agreement 
with the tropism of OrV. Intestinal GFP was most often visible around the collar of the nematodes, in the
anterior region of the intestine in young adults. Some infected individuals exhibited a strong GFP signal
throughout their entire body (data not shown), suggesting that the induction of the viral stress sensor
can spread from cell to cell, like an inflammation process. The viral stress sensor offers an opportunity to
easily monitor viral infections in living animals. 
 
 
 
 
Click inside this box and insert a single image for Supplementary Figure 2.  
 
 
Supplementary Figure 2 
 
 
A cde-1 deletion allele fails to complement the screen isolate ovid-9. 
a, Workflow of cde-1/ovid-9 (mj414) × cde-1 (tm1021) F8 recombinant family generation. A similar
strategy was used to construct the cde-1 (mj414) × drh-1 (ok3495) F8 recombinant families. All animals 
were homozygous for the viral stress sensor (mjIs228). 
b-c, Number of families that activated the viral stress sensor in more than 20% of individuals after four
days of infection with OrV. Approximately 50 individuals scored per family. Bars: number of families
meeting criteria as indicated. 
 
 
 
Click inside this box and insert a single image for Supplementary Figure 3.  
 
 
 
 
Supplementary Figure 3 
cde-1 mutants show horizontal transmission of Orsay virus infection. 
Workflow and data monitoring the inter-individual transmission of OrV infection (in strains as indicated) 
using the viral stress sensor. 
 
 
 
Click inside this box and insert a single image for Supplementary Figure 4.  
Supplementary Figure 4 
Intestinal expression of cde-1 confers antiviral immunity. 
a, Representative confocal sections (20× magnification) of OrV in vivo RNA FISH. 
 
 
b, Representative confocal section (10× magnification) of a C. elegans L4 larva expressing cde-1::GFP. As 
two previous reports disagreed about the expression pattern of CDE-1 (Olsen, A. et al. Science 312, 1381–
1385, 2006; van Wolfswinkel, J. C. et al. Cell 139, 135–148, 2009), we used fosmid-recombineering to 
generate transgenic animals driving GFP expression from an endogenous genomic context. 
c, Diagram of the cde-1 rescue transgene, using the intestine-specific promoter of the gene vha-6. This 
transgene was injected in cde-1 null mutants. 
d, Viral load as measured by qRT-PCR of OrV RNA1 genome in adults two days after infection. Bars: 
average value; error: SEM; five independent infections. One-tailed student’s t-test: *** p<0.001, **p<0.01.
e, Incidence of male in the progeny of hermaphrodites left to self-fertilize at 25°C, in strains as indicated. 
 
 
 
Click inside this box and insert a single image for Supplementary Figure 5.  
Supplementary Figure 5 
CDE-1 is not required for general miRNA homeostasis. 
a, Non-templated nucleotides at the 3ʹ end of the different classes of endogenous and antiviral small
RNAs as indicated. RNA was isolated from young adults after two days of infection with OrV. 
b, miRNA expression in cde-1 (tm1021) mutants as compared to wild type, samples as in a. Dots: 
individual miRNA; reads per million averaging two independent C. elegans culture plates. 
 
 
c, piRNAs and endogenous 22G-RNAs abundance in cde-1 (tm1021) mutants as compared to wild type, 
normalised to library size. Dots: independent C. elegans culture plate. Samples as in a. 
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Supplementary Figure 6 
CDE-1-depleted animals show a high expression of stress response genes during Orsay virus infection 
a, Fold change in the length of poly(A) tails (measured by TAIL-seq) in cde-1 mutants compared to wild
type. RNA was isolated from young adults after two days of OrV infection. Turkey boxplot. 
b, Differential mRNA expression in cde-1 (tm1021) compared to wild type, two days of OrV infection
(mRNA-seq). Turkey boxplot; dots: outliers. 
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Supplementary Figure 7 
The 3ʹ end of the Orsay virus genome contains CDE-1-dependent non-templated U-tails 
a, Simplified workflow of 3ʹ RACE-seq of OrV RNA1 and OrV RNA2. 
b-c, Comparison between the viral load and the fraction of non-templated mono(U) tails at the 3ʹ end of 
OrV RNA1 and OrV RNA2, respectively, in strains as indicated. Dots: independent infection. Samples as in 
Fig. 3d,e and Fig. 4e. 
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Supplementary Figure 8 
The terminal uridylyltransferases TUT4(7) restrict Influenza A infection 
a, Protein level of the IAV NP measured by immunofluorescence (FACS). Error: SEM in three independent 
infections. 
b, Level of expression of the IAV NP mRNA normalized to Gapdh in MEF cells of different genotypes as 
indicated. Bars: average value; error: SEM; three independent infections. 
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Supplementary	Table	1	|	Infection	by	the	Orsay	virus	induces	viral	stress	sensor	in	Ovid	screen	
isolates.	Strain	 Genotype	 %	intestinal	GFP	mock	 %	intestinal	GFP	OrV	SX2635	 WT	 0	 4	SX2615	 rde-1	 0	 42	SX2790	 drh-1	 0	 83	SX2996	 ovid-1	 0	 86	SX2900	 ovid-2	 0	 83	SX2739	 ovid-3	 0	 74	SX2901	 ovid-4	 0	 73	SX2902	 ovid-5	 0	 68	SX2729	 ovid-6	 0	 64	SX2991	 ovid-7	 0	 	 	60	SX2990	 ovid-8	 0	 52	SX3000	 ovid-9	 0	 48	SX2881	 ovid-10	 0	 47	SX2987	 ovid-11	 0	 46	SX2988	 ovid-12	 0	 44	SX2920	 ovid-13	 0	 26	SX2909	 ovid-14	 0	 26	SX2886	 ovid-15	 0	 24	SX2885	 ovid-16	 0	 24	
	The	percentage	of	young	adults	exhibiting	intestinal	GFP	was	assessed	after	four	days	of	infection	by	OrV	or	in	non-infected	animals	(mock).	20	to	50	young	adults	were	scored	per	plate,	in	three	independent	infections	(average	values	are	shown	here).	The	screen	isolates	ovid-1,7,8,9,11,12	were	backcrossed	prior	to	GFP	scoring	(see	Supplementary	Table	2).		
	
	
	
	
	
	
	
 
 
Supplementary	Table	2	|	C.	elegans	strains	used	in	this	study	Genotype	 Strain	 Comment	+	 N2	 		
cde-1(mj453)	III	 SX3186	 		
cde-1(tm1021)	III	 RF1290	 		
cde-1(tm1021)	III	;	drh-1(ok3495)	IV	 SX2998	 		
cde-1(tm1021)	III	;	mjEx595	 SX3265	 Contains	the	intestine-specific	cde-1	construct	(vha-6p::cde-1)	
cde-1(tm1021)	III	;	mjIs228	?	 SX2999	 		
cde-1(tm1021)	III	;	rde-1(ne219)	V	 SX3004	 		
drh-1(ok3495)	IV	 RB2519	 		
drh-1(ok3495)	IV	;	mjIs228	?	 SX2790	 		F27D4.6(tm1098)	I	 FX01098	 		
mjEx594	?	 SX3123	 Contains	the	cde-1::GFP	fosmid	(TransgeneOme	construct)	
mjIs228	?	 SX2635	 Contains	the	biostress	(lys-
3p::GFP)	reporter	
ovid-1(mj417)	 SX2996	 Backcrossed	2X	to	SX2635	
ovid-2(mj422)	 SX2900	 		
ovid-3(mj367)	 SX2739	 		
ovid-4(mj423)	 SX2901	 		
ovid-5(mj425)	 SX2902	 		
ovid-6(mj357)	 SX2729	 		
ovid-7(mj405)	 SX2991	 Backcrossed	2X	to	SX2635	
ovid-8(mj369)	 SX2990	 Backcrossed	2X	to	SX2635	
ovid-9(mj414)	 SX3000	 Backcrossed	2X	to	SX2635	
ovid-10(mj403)	 SX2881	 		
ovid-11(mj354)	 SX2987	 Backcrossed	3X	to	SX2635	
ovid-12(mj401)	 SX2988	 Backcrossed	3X	to	SX2635	
ovid-13(mj432)	 SX2920	 		
ovid-14(mj431)	 SX2909	 		
ovid-15(mj408)	 SX2886	 		
ovid-16(mj407)	 SX2885	 		
rde-1(ne219)	V	 WM27	 		
rde-1(ne219)	V	;	
mjIs228	?	
SX2615	 		
	
 
 
	
Supplementary	Table	3	|	Primers	used	in	this	study	Name	 Sequence	 Description	M1835	 TGGAGCCGACTATGTCGTTGAG	 RT-qPCR	on	gapdh	-	left	M1836	 GCAGATGGAGCAGAGATGATGAC	 RT-qPCR	on	gapdh	-	right	M4410	 ACCTCACAACTGCCATCTACA	 RT-qPCR	OrV	RNA1	-	left	M4411	 	 	GACGCTTCCAAGATTGGTATT	 RT-qPCR	OrV	RNA1	-	right	M4988	 CAATGCATTTGAAGCTGGAC	 RT-qPCR	on	lys-3	-	left	M4989	 CCATTAGCAAGCAAATTCTGG	 RT-qPCR	on	lys-3	-	right	M5041	 ACAATCGGGCGTTCAATTC	 RT-qPCR	on	sdz-6	-	left	M5042	 TCTGATAGCTGGCTGAGTGG	 RT-qPCR	on	sdz-6	-	right	M5472	 GGGGACAACTTTGTATAGAAAAGTTGCTTCGAAAGAAACCCAATCCTC	 cloning	of	lys-3p	into	gateway	system	-	left	M5473	 GGGGACTGCTTTTTTGTACAAACTTGGAGGAGCTGGGAAAGAGTAGCA	 cloning	of	lys-3p	into	gateway	system	-	right	M7316	 CCGGAACCCATCACGAAATT	 PCR	on	cde-1	(mj414)	for	Sanger	sequencing	-	left	M7317	 TCCATTTCAAAGTCTCCACAGA	 PCR	on	cde-1	(mj414)	for	Sanger	sequencing	-	right	M7454	 ATGGCCAAACGTCTGAAACC	 OrV	RNA1	3ʹ	RACE	-	left	M7455	 CCAAAGTCGCTTGCTGTACA	 OrV	RNA2	3ʹ	RACE	-	left	M7456	 CCTTGGCACCCGAGAATTCCA	 OrV	RNA1/2	3ʹ	RACE	-	right	M7601	 GTTCAGAGTTCTACAGTCCGACGATCATGGCCAAACGTCTGAAACC	 OrV	RNA1	3ʹ	RACE	(with	TruSeq	RA5	sequence)	-	left	M7602	 GTTCAGAGTTCTACAGTCCGACGATCCCAAAGTCGCTTGCTGTACA	 OrV	RNA2	3ʹ	RACE	(with	TruSeq	RA5	sequence)	-	left	M8443	 GCTAATTGGGCAAGGAGACG	 IAV	3'	RACE	PB2	RNA	complementary	left			M8444	 GCTGGGTTCTTCTCCTGTCT	 IAV	3'	RACE	PB2	RNA	genomic	left			M8451	 CTCTCGGACGAAAAGGCAAC	 IAV	3'	RACE	NP	RNA	complementary	left			M8452	 AAGTTCGGTGCACATTTGGA	 IAV	3'	RACE	NP	RNA	genomic	left			M8453	 CGCAATCTGGACTAGTGGGA	 IAV	3'	RACE	NA	RNA	complementary	left			M8454	 GCCTTGGTTGCATATTCCAGT	 IAV	3'	RACE	NA	RNA	genomic	left			M8455	 ACGGTTTGAAAAGAGGGCCT	 IAV	3'	RACE	MP	RNA	complementary	left			M8456	 CGGTGTTCTTCCCTGCAAAG	 IAV	3'	RACE	MP	RNA	genomic	left			M8459	 GTTCAGAGTTCTACAGTCCGACGATCgctaattgggcaaggagacg	 IAV	3'	RACE	PB2	RNA	complementary	left		(with	TruSeq	RA5	sequence)		
 
 
M8460	 GTTCAGAGTTCTACAGTCCGACGATCgctgggttcttctcctgtct	 IAV	3'	RACE	PB2	RNA	genomic	left		(with	TruSeq	RA5	sequence)		M8467	 GTTCAGAGTTCTACAGTCCGACGATCctctcggacgaaaaggcaac	 IAV	3'	RACE	NP	RNA	complementary	left		(with	TruSeq	RA5	sequence)		M8468	 GTTCAGAGTTCTACAGTCCGACGATCaagttcggtgcacatttgga	 IAV	3'	RACE	NP	RNA	genomic	left		(with	TruSeq	RA5	sequence)		M8469	 GTTCAGAGTTCTACAGTCCGACGATCcgcaatctggactagtggga	 IAV	3'	RACE	NA	RNA	complementary	left		(with	TruSeq	RA5	sequence)		M8470	 GTTCAGAGTTCTACAGTCCGACGATCgccttggttgcatattccagt	 IAV	3'	RACE	NA	RNA	genomic	left		(with	TruSeq	RA5	sequence)		M8471	 GTTCAGAGTTCTACAGTCCGACGATCacggtttgaaaagagggcct	 IAV	3'	RACE	MP	RNA	complementary	left		(with	TruSeq	RA5	sequence)		M8472	 GTTCAGAGTTCTACAGTCCGACGATCcggtgttcttccctgcaaag	 IAV	3'	RACE	MP	RNA	genomic	left		(with	TruSeq	RA5	sequence)		M8652	 CCTTCCACAATGCCAAAGTT	 	gapdh	gene	specific	RT	primer	M8581	 CCAGATCGTTCGAGTCGTTTTTTTTTTTTTTTTTCTTTAATTGTC	 IAV	NP	mRNA	gene	specific	RT	primer	M8651	 GGGTGTGAACCACGAGAAAT	 gapdh	qRT-PCR	primer	left	M8652	 CCTTCCACAATGCCAAAGTT	 gapdh	qRT-PCR	primer	right	M8582	 CCAGATCGTTCGAGTCGT	 IAV	NP	mRNA	qRT-PCR	primer	left	M8583	 CGATCGTGCCCTCCTTTGCGATCGTGCCCTCCTTTG	 IAV	NP	mRNA	qRT-PCR	primer	right	HJ359	 GATGGACAAACAGACAAACC	 Tut4-1GTF	genotyping	HJ360	 GCAGTTGTGCTATATTGACTC	 Tut4-1GTR	genotyping	HJ365	 TGATCAGAGCATGCATACTC	 Tut7-2GTF	genotyping	HJ366	 AAACAAGAAGCAGAGGTCCA	 Tut7-2GTR	genotyping			
